強生 |
Johnson & Johnson |
????2012年《財富》500強排名:第41位 ????2012年利潤(單位:百萬美元):10,853 ????現(xiàn)在回過頭來看,,強生在2012年4月任命亞歷克斯?戈爾斯基為新任CEO對這個醫(yī)藥公司來說是件好事。2012年,強生實現(xiàn)利潤108.5億美元,,較2011年的97億美元躍升了12%,。2011年,強生遭遇了一系列質(zhì)量問題,、召回事件,、負面影響頗大的公共調(diào)查。相比之下,,它在2012年的運營更為平穩(wěn),,還斥資197億美元吞并了醫(yī)療設(shè)備生產(chǎn)廠辛迪思(Synthes),當然業(yè)務(wù)也出現(xiàn)了轉(zhuǎn)機,。雖然2013年第一季度的利潤較2012年同期下降了11%,,但銷售額卻提高了?!狣.R. |
????Fortune 500 rank: 41 ????2012 profit (millions): 10,853 ????It now looks, in hindsight, like the appointment of new CEO Alex Gorsky in April 2012 was a good thing for the drug-maker: profits in 2012 went up to $10.85 billion, a 12% jump over 2011's $9.7 billion. In 2011 the company had to handle a number of quality issues and recalls, as well as public and damaging investigations. 2012, in contrast, brought smoother operations, a $19.7 billion buyout of medical device-maker Synthes, and clearly, something of a turnaround. And although Q1 profits for 2013 were down 11% vs. Q1 in 2012, sales were up. --D.R. |